Key facts
- This page summarizes Jean-Pierre Bizzari's Form 4 filing for HALOZYME THERAPEUTICS, INC. (HALO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 May 2023, 18:09.
Jean-Pierre Bizzari - 05 May 2023 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)
- Reporting relationship
- Director
- Issuer ticker
- HALO
- Reported as of
- 05 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 May 2023, 18:09:24 UTC
- Prior SEC filing
- 06 May 2022
- Next SEC filing
- 24 Aug 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Oehler, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jean-Pierre Bizzari filed Form 4 for HALOZYME THERAPEUTICS, INC. (HALO) on 09 May 2023.
Change
- Previous filing in this sequence was filed on 06 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HALO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,065
- Change %
- +14%
- Price
- $0.000000
- Shares after
- 66,815
- Date
- 05 May 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HALO
transaction
Derivative
Option to Purchase Common Stock
Award
- Transaction value
- $0
- Shares
- +11,371
- Change %
- Price
- $0.000000
- Shares after
- 11,371
- Date
- 05 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,371
- Exercise price
- $31.00
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.
Footnote F2
Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders.